GlassScriptPhysician profile
Amit D Kalra
NPI 1215120274
$14,428.93
in general payments reported to CMS, 2019-2025
39 companies · $3,053 in 2025
The $3,053 reported for 2025 was more than what 87% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,543 · 2020: $395 · 2021: $327 · 2022: $1,408 · 2023: $2,621 · 2024: $3,083 · 2025: $3,053.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,583 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,582.66 |
| Education | $174.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,828.52 | 2019-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $2,020.70 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Allergan, INC. | $1,946.71 | 2019 | |
| Abbvie INC. | $1,416.26 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,022.45 | 2019-2025 | Xifaxan, Plenvu |
| Pfizer INC. | $859.78 | 2019-2025 | |
| Celgene Corporation | $436.74 | 2022-2024 | Zeposia |
| Ardelyx, INC. | $421.55 | 2022-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $405.09 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $362.23 | 2022-2025 | Dupixent |
| Genzyme Corporation | $256.18 | 2022-2025 | |
| Gilead Sciences, INC. | $226.65 | 2019-2025 | |
| Qol Medical, LLC | $202.15 | 2019-2025 | Sucraid, Sucraid |
| Lilly USA, LLC | $200.47 | 2024-2025 | Omvoh, Mounjaro, Zepbound |
| Madrigal Pharmaceuticals | $190.40 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sonendo INC | $169.18 | 2023 | Gentlewave G4 Console, Gentlewave Console |
| Ipsen Biopharmaceuticals, INC | $156.74 | 2025 | Iqirvo |
| Braintree Laboratories, INC. | $132.59 | 2019-2023 | Sutab |
| Ironwood Pharmaceuticals, INC | $127.55 | 2022-2024 | Linzess |
| Celltrion USA INC. | $123.57 | 2023-2025 | Vegzelma, Yuflyma |
| Intercept Pharmaceuticals, INC. | $120.90 | 2019-2025 | Ocaliva |
| Janssen Scientific Affairs, LLC | $116.14 | 2019 | |
| Daiichi Sankyo INC. | $110.87 | 2019-2022 | |
| Pentax of America, INC. | $80.51 | 2025 | Pentax Medical, C2 Cryoballoon, C2 Cryoballoon Focal Controller |
| Evoke Pharma, INC. | $73.54 | 2022-2025 | Gimoti |
| Merck Sharp & Dohme LLC | $72.04 | 2019-2023 | Dificid |
| Fresenius Kabi USA, LLC | $71.62 | 2023-2024 | Idacio |
| Organon LLC | $53.11 | 2022-2023 | Hadlima |
| Tersera Therapeutics LLC | $35.73 | 2024 | Xermelo |
| Boston Scientific Corporation | $33.20 | 2025 | Solyx Sis System |
| W. L. Gore & Associates, INC. | $32.75 | 2023 | Gore Cardioform Septal Occluder |
| Laborie Medical Technologies Corp. | $23.27 | 2025 | |
| Ucb, INC. | $19.71 | 2019 | |
| Alexion Pharmaceuticals, INC. | $19.57 | 2023 | Ultomiris |
| Tactile Systems Technology INC | $16.12 | 2020 | |
| Amgen INC. | $15.88 | 2025 | |
| Ferring Pharmaceuticals INC. | $14.60 | 2019 | |
| Vivus LLC | $13.86 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$50,461.91 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Kalra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.